3.64
price up icon0.28%   0.01
after-market Handel nachbörslich: 3.68 0.04 +1.10%
loading

Xenetic Biosciences Inc Aktie (XBIO) Neueste Nachrichten

pulisher
12:09 PM

Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform - Greenville Online

12:09 PM
pulisher
Jul 23, 2025

Xenetic Biosciences Inc. Stock Analysis and ForecastHigh-yield market plays - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

Xenetic expands DNase-I collaboration with Scripps Research By Investing.com - Investing.com South Africa

Jul 23, 2025
pulisher
Jul 23, 2025

Revolutionary Cancer Treatment: Xenetic and Scripps Advance DNase-CAR-T Therapy for Lymphoma and Leukemia - Stock Titan

Jul 23, 2025
pulisher
Jul 23, 2025

What drives Xenetic Biosciences Inc. stock priceExceptional portfolio growth - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

What analysts say about Xenetic Biosciences Inc. stockRobust investment performance - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Is Xenetic Biosciences Inc. a good long term investmentConsistently exceptional gains - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 16, 2025

Why Xenetic Biosciences Inc. stock attracts strong analyst attentionLow Risk High Reward Picks - Newser

Jul 16, 2025
pulisher
Jul 15, 2025

What makes Xenetic Biosciences Inc. stock price move sharplyFree Exclusive Investment Tips - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Xenetic Biosciences Inc. stock performs during market volatilityOptimized Return Investment Picks - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Xenetic Biosciences (NASDAQ:XBIO) Shares Down 8% – What’s Next? - Defense World

Jul 15, 2025
pulisher
Jul 12, 2025

Head to Head Comparison: Xenetic Biosciences (NASDAQ:XBIO) versus Vaxart (NASDAQ:VXRT) - Defense World

Jul 12, 2025
pulisher
Jul 09, 2025

Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic C - The Holland Sentinel

Jul 09, 2025
pulisher
Jul 09, 2025

New to The Street Announces Media Coverage of BitMine Immersion Technologies Inc., Including NewsOut Video PR Integration - Great Falls Tribune

Jul 09, 2025
pulisher
Jul 08, 2025

North Shore Uranium Engages Investing News Network - Great Falls Tribune

Jul 08, 2025
pulisher
Jul 08, 2025

LQR House Announces Strategic Marketing Cooperation with Montauk Distilling Co. for Cinnamon Flavored Rum - Great Falls Tribune

Jul 08, 2025
pulisher
Jul 08, 2025

Monogram Technologies Announces the Mandatory Conversion of 8.00% Series D Convertible Cumulative Preferred Stock - Great Falls Tribune

Jul 08, 2025
pulisher
Jul 08, 2025

Groundbreaking Pancreatic Cancer Trial Launches: DNase I Combined With FOLFIRINOX in Advanced Cases - Stock Titan

Jul 08, 2025
pulisher
Jul 07, 2025

Unusual Machines Inc. Promotes Stacy Wright to Executive Vice President of Revenue as Company Scales U.S. Footprint and Prepares for Accelerated Growth - Great Falls Tribune

Jul 07, 2025
pulisher
Jun 25, 2025

Xenetic Biosciences’ 13.5% Surge: What’s Driving the Unexplained Rally? - AInvest

Jun 25, 2025
pulisher
Jun 24, 2025

Pre-market Movers: NKTR, INM, IBIO, IBO... - RTTNews

Jun 24, 2025
$23.63
price up icon 3.30%
$36.59
price up icon 1.58%
$103.52
price up icon 0.10%
$27.57
price down icon 1.54%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.65%
Kapitalisierung:     |  Volumen (24h):